US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

48.69

+0.13000.27%

Post-market: 48.690.00000.00%19:30 EDT

Volume:294.75K

Turnover:14.35M

Market Cap:2.34B

PE:-15.95

High:50.34

Open:48.50

Low:47.73

Close:48.56

52wk High:52.93

52wk Low:14.11

Shares:47.98M

Float Shares:30.39M

Volume Ratio:1.08

T/O Rate:0.97%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.0525

EPS(LYR):-2.8633

ROE:-39.96%

ROA:-25.78%

PB:5.52

PE(LYR):-17.00

Loading ...

Overview Company News Filings

Rapport Therapeutics shareholders elected Class II directors at annual meeting

Rapport Therapeutics (RAPP) Is Down 9% After Strong RAP-219 Data Outshines Rival Trial - Has The Bull Case Changed?

Simply Wall St.

RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy

BTIG Reaffirms Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)

Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $743,673.08

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from BTIG

Rapport Therapeutics Is Maintained at Buy by BTIG

Rapport Therapeutics to present at Jefferies Global Healthcare Conference fireside chat

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference

Rapport Therapeutics Coverage Assumed by Truist Securities at Buy

Rapport Therapeutics assumed with a Buy at Truist

Third Rock Ventures V disposes 133,618 Rapport Therapeutics shares for $5.38 million

Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $11,096,094.77

Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG

Rapport Therapeutics, Inc. (RAPP) Gets a Buy from JonesTrading

Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile

Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market

Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)

Rapport Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Rapport Therapeutics Q1 FY26 net loss narrows to $19.9 million; revenue rises to $20 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/RAPP/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":48.69,"timestamp":1788379200000,"preClose":48.56,"halted":0,"volume":294754,"hourTrading":{"tag":"盘后","latestPrice":48.69,"preClose":48.69,"latestTime":"19:30 EDT","volume":2926,"amount":142510.52,"timestamp":1788391805961,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0026771004942338435,"floatShares":30393800,"shares":47978286,"eps":-3.052456,"marketStatus":"Not Yet Opened","change":0.13,"latestTime":"09-02 16:00:00 EDT","open":48.5,"high":50.34,"low":47.73,"amount":14349895.10974,"amplitude":0.053748,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.052456,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788422400000},"marketStatusCode":0,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":48.56,"postHourTrading":{"tag":"盘后","latestPrice":48.69,"preClose":48.69,"latestTime":"19:30 EDT","volume":2926,"amount":142510.52,"timestamp":1788391805961,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.083291,"impliedVol":1.2635,"impliedVolPercentile":0.9841},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":30393800,"roa":"-25.78%","roe":"-39.96%","lyrEps":-2.863342,"volumeRatio":1.083291,"shares":47978286,"dividePrice":0,"high":50.34,"amplitude":0.053748,"preClose":48.56,"low":47.73,"week52Low":14.11,"pbRate":"5.52","psRate":"116.80","week52High":52.93,"institutionHeld":0,"latestPrice":48.69,"eps":-3.052456,"divideRate":0,"volume":294754,"delay":0,"ttmEps":-3.052456,"open":48.5,"prevYearClose":30.34,"prevWeekClose":48.77,"prevMonthClose":48.67,"prevQuarterClose":41.67,"fiveDayClose":52.5,"twentyDayClose":42.44,"sixtyDayClose":36.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-05","symbol":"RAPP","fiscalQuarterEnding":"2026/06","expectedEps":-0.93,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785902400000,"reportTimeType":"pre","actualEps":-1.19},{"market":"US","date":"2026-05-07","symbol":"RAPP","fiscalQuarterEnding":"2026/03","expectedEps":-0.56,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.42},{"market":"US","date":"2026-03-10","symbol":"RAPP","fiscalQuarterEnding":"2025/12","expectedEps":-0.65,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"pre","actualEps":-0.72},{"market":"US","date":"2025-11-06","symbol":"RAPP","fiscalQuarterEnding":"2025/09","expectedEps":-0.77,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.71},{"market":"US","date":"2025-08-07","symbol":"RAPP","fiscalQuarterEnding":"2025/06","expectedEps":-0.87,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.75}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4615,"buy":0.5385,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5385,"analysts":13,"updateTime":1785211200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2026-09-01","current":-15.95109,"percent":0.110714,"low":-19.654107,"twenty":-15.697551,"median":-12.878752,"eighty":-6.429372,"high":-3.640031,"avg":-11.729442,"sd":4.390558,"marketCap":2335103179},"quantilePoints":[{"date":"2024-06-07","current":-14.341434,"twenty":-13.293406,"median":-11.721364,"eighty":-11.721364,"marketCap":735830305},{"date":"2024-06-14","current":-17.322989,"twenty":-16.966549,"median":-15.024031,"eighty":-12.769392,"marketCap":888807905},{"date":"2024-06-21","current":-15.733266,"twenty":-17.881887,"median":-15.772475,"eighty":-14.348329,"marketCap":807242405},{"date":"2024-06-28","current":-16.581593,"twenty":-17.17471,"median":-16.18238,"eighty":-14.635158,"marketCap":850768389},{"date":"2024-07-05","current":-17.059223,"twenty":-17.829134,"median":-16.431888,"eighty":-15.672154,"marketCap":875274616},{"date":"2024-07-12","current":-18.299635,"twenty":-18.057796,"median":-16.595851,"eighty":-15.733266,"marketCap":938917651},{"date":"2024-07-19","current":-14.343149,"twenty":-18.092899,"median":-16.610109,"eighty":-15.733266,"marketCap":735918314},{"date":"2024-07-26","current":-16.431888,"twenty":-18.057796,"median":-16.50674,"eighty":-14.592658,"marketCap":843087333},{"date":"2024-08-02","current":-15.740395,"twenty":-18.021611,"median":-16.417631,"eighty":-14.614044,"marketCap":807608170},{"date":"2024-08-09","current":-11.062669,"twenty":-17.829134,"median":-16.189509,"eighty":-14.507112,"marketCap":697147270},{"date":"2024-08-16","current":-12.078391,"twenty":-17.822005,"median":-15.897228,"eighty":-14.341434,"marketCap":761156070},{"date":"2024-08-23","current":-12.943207,"twenty":-17.322989,"median":-15.776039,"eighty":-12.769083,"marketCap":815654991},{"date":"2024-08-30","current":-12.623979,"twenty":-17.301602,"median":-15.672154,"eighty":-12.252515,"marketCap":795537939},{"date":"2024-09-06","current":-11.799793,"twenty":-17.107699,"median":-14.956226,"eighty":-12.030797,"marketCap":743599370},{"date":"2024-09-13","current":-11.027844,"twenty":-17.007896,"median":-14.603351,"eighty":-11.813723,"marketCap":694952683},{"date":"2024-09-20","current":-12.322165,"twenty":-16.6871,"median":-14.421566,"eighty":-11.752199,"marketCap":776518182},{"date":"2024-09-27","current":-12.380206,"twenty":-16.587296,"median":-14.342291,"eighty":-11.752199,"marketCap":780175827},{"date":"2024-10-04","current":-12.072587,"twenty":-16.581593,"median":-13.041877,"eighty":-11.742318,"marketCap":760790305},{"date":"2024-10-11","current":-12.798103,"twenty":-16.461829,"median":-12.783593,"eighty":-11.721364,"marketCap":806510876},{"date":"2024-10-18","current":-15.061713,"twenty":-16.461829,"median":-13.041877,"eighty":-11.742318,"marketCap":949159059},{"date":"2024-10-25","current":-14.057599,"twenty":-16.431888,"median":-14.106934,"eighty":-11.752199,"marketCap":885881788},{"date":"2024-11-01","current":-14.289764,"twenty":-16.420482,"median":-14.289764,"eighty":-11.78122,"marketCap":900512371},{"date":"2024-11-08","current":-13.587752,"twenty":-16.360601,"median":-14.196898,"eighty":-11.792828,"marketCap":976225637},{"date":"2024-11-15","current":-10.665545,"twenty":-16.293733,"median":-13.709352,"eighty":-11.752199,"marketCap":766276774},{"date":"2024-11-22","current":-11.755009,"twenty":-16.213426,"median":-13.641207,"eighty":-11.719637,"marketCap":844550392},{"date":"2024-11-29","current":-11.627735,"twenty":-16.188083,"median":-13.405914,"eighty":-11.573511,"marketCap":835406277},{"date":"2024-12-06","current":-10.416089,"twenty":-16.139607,"median":-12.943207,"eighty":-11.450385,"marketCap":748354310},{"date":"2024-12-13","current":-9.555718,"twenty":-15.982774,"median":-12.73716,"eighty":-11.371152,"marketCap":686540097},{"date":"2024-12-20","current":-9.199351,"twenty":-15.858733,"median":-12.415031,"eighty":-11.254059,"marketCap":660936577},{"date":"2024-12-27","current":-9.688083,"twenty":-15.824515,"median":-12.350651,"eighty":-11.045256,"marketCap":696049976},{"date":"2025-01-03","current":-9.917175,"twenty":-15.797425,"median":-12.316361,"eighty":-10.975704,"marketCap":712509382},{"date":"2025-01-10","current":-7.539701,"twenty":-15.740395,"median":-12.304752,"eighty":-10.859002,"marketCap":541697328},{"date":"2025-01-17","current":-6.460419,"twenty":-15.733266,"median":-12.215086,"eighty":-10.644772,"marketCap":464155239},{"date":"2025-01-24","current":-7.076424,"twenty":-15.684376,"median":-12.087097,"eighty":-10.43238,"marketCap":508412752},{"date":"2025-01-31","current":-8.354253,"twenty":-15.597056,"median":-11.915876,"eighty":-10.137105,"marketCap":600219659},{"date":"2025-02-07","current":-8.211706,"twenty":-15.257893,"median":-11.843324,"eighty":-9.686047,"marketCap":589978251},{"date":"2025-02-14","current":-8.094614,"twenty":-15.103195,"median":-11.828814,"eighty":-9.441681,"marketCap":581565666},{"date":"2025-02-21","current":-6.455328,"twenty":-15.070846,"median":-11.799793,"eighty":-9.297098,"marketCap":463789474},{"date":"2025-02-28","current":-5.106225,"twenty":-15.037336,"median":-11.771597,"eighty":-9.077168,"marketCap":366861863},{"date":"2025-03-07","current":-4.373128,"twenty":-15.01412,"median":-11.747556,"eighty":-8.771711,"marketCap":314191765},{"date":"2025-03-14","current":-4.898381,"twenty":-14.977526,"median":-11.717047,"eighty":-8.416363,"marketCap":383577552},{"date":"2025-03-21","current":-4.530187,"twenty":-14.817535,"median":-11.627735,"eighty":-8.164869,"marketCap":354745367},{"date":"2025-03-28","current":-4.68399,"twenty":-14.676319,"median":-11.461087,"eighty":-7.790176,"marketCap":366789191},{"date":"2025-04-04","current":-4.189957,"twenty":-14.640334,"median":-11.410917,"eighty":-7.133443,"marketCap":328102968},{"date":"2025-04-11","current":-4.315796,"twenty":-14.632186,"median":-11.370643,"eighty":-6.989878,"marketCap":337957006},{"date":"2025-04-17","current":-4.730597,"twenty":-14.622599,"median":-11.327444,"eighty":-6.74653,"marketCap":370438835},{"date":"2025-04-25","current":-4.949801,"twenty":-14.60549,"median":-11.189913,"eighty":-6.457364,"marketCap":387604034},{"date":"2025-05-02","current":-5.280719,"twenty":-14.55844,"median":-11.048158,"eighty":-5.528775,"marketCap":413517298},{"date":"2025-05-09","current":-4.693792,"twenty":-14.472894,"median":-10.976093,"eighty":-5.332796,"marketCap":374099938},{"date":"2025-05-16","current":-4.560992,"twenty":-14.4176,"median":-10.940782,"eighty":-5.2164,"marketCap":363515647},{"date":"2025-05-23","current":-5.092192,"twenty":-14.397354,"median":-10.8247,"eighty":-5.097805,"marketCap":405852811},{"date":"2025-05-30","current":-3.896992,"twenty":-14.370288,"median":-10.665545,"eighty":-4.981023,"marketCap":310594193},{"date":"2025-06-06","current":-5.646289,"twenty":-14.346875,"median":-10.527934,"eighty":-4.950803,"marketCap":450014853},{"date":"2025-06-13","current":-5.101351,"twenty":-14.342806,"median":-10.416089,"eighty":-4.981023,"marketCap":406582762},{"date":"2025-06-20","current":-5.050978,"twenty":-14.341434,"median":-10.309179,"eighty":-5.014344,"marketCap":402568031},{"date":"2025-06-27","current":-5.408165,"twenty":-14.289764,"median":-9.866266,"eighty":-5.000606,"marketCap":431036124},{"date":"2025-07-03","current":-5.513507,"twenty":-14.247974,"median":-9.698265,"eighty":-5.011596,"marketCap":439432031},{"date":"2025-07-11","current":-7.043002,"twenty":-14.172521,"median":-9.586263,"eighty":-5.043651,"marketCap":561334272},{"date":"2025-07-18","current":-6.795718,"twenty":-14.077333,"median":-9.430989,"eighty":-5.078884,"marketCap":541625526},{"date":"2025-07-25","current":-7.610838,"twenty":-13.779001,"median":-9.362262,"eighty":-5.090926,"marketCap":606591391},{"date":"2025-08-01","current":-6.57591,"twenty":-13.6976,"median":-9.168805,"eighty":-5.092192,"marketCap":524106641},{"date":"2025-08-08","current":-6.368661,"twenty":-13.694662,"median":-9.054259,"eighty":-5.099519,"marketCap":562429202},{"date":"2025-08-15","current":-6.17446,"twenty":-13.609134,"median":-8.982986,"eighty":-5.10525,"marketCap":545278924},{"date":"2025-08-22","current":-6.170327,"twenty":-13.473486,"median":-8.4968,"eighty":-5.115317,"marketCap":544913945},{"date":"2025-08-29","current":-6.943168,"twenty":-13.38251,"median":-8.407708,"eighty":-5.122916,"marketCap":613165056},{"date":"2025-09-05","current":-6.343907,"twenty":-13.171889,"median":-8.282979,"eighty":-5.126995,"marketCap":560243072},{"date":"2025-09-12","current":-9.588184,"twenty":-13.020376,"median":-8.364435,"eighty":-5.143059,"marketCap":846751744},{"date":"2025-09-19","current":-14.281097,"twenty":-13.398113,"median":-8.486618,"eighty":-5.165131,"marketCap":1261192245},{"date":"2025-09-26","current":-13.038354,"twenty":-13.650327,"median":-8.934622,"eighty":-5.176938,"marketCap":1151443158},{"date":"2025-10-03","current":-14.902468,"twenty":-13.718742,"median":-9.051713,"eighty":-5.195691,"marketCap":1316066789},{"date":"2025-10-10","current":-13.962579,"twenty":-13.896787,"median":-9.158623,"eighty":-5.223161,"marketCap":1233063277},{"date":"2025-10-17","current":-12.986138,"twenty":-13.856058,"median":-9.228454,"eighty":-5.262092,"marketCap":1146831851},{"date":"2025-10-24","current":-13.675391,"twenty":-13.856058,"median":-9.397898,"eighty":-5.294604,"marketCap":1207701093},{"date":"2025-10-31","current":-14.035682,"twenty":-13.934383,"median":-9.502263,"eighty":-5.303959,"marketCap":1239519106},{"date":"2025-11-07","current":-11.969573,"twenty":-13.970933,"median":-9.588184,"eighty":-5.319746,"marketCap":1169427252},{"date":"2025-11-14","current":-12.034803,"twenty":-13.934383,"median":-9.698265,"eighty":-5.33408,"marketCap":1175800274},{"date":"2025-11-21","current":-13.098276,"twenty":-13.915585,"median":-9.917175,"eighty":-5.342242,"marketCap":1279701555},{"date":"2025-11-28","current":-14.493474,"twenty":-13.931568,"median":-10.309179,"eighty":-5.356195,"marketCap":1416012409},{"date":"2025-12-05","current":-14.000764,"twenty":-13.954437,"median":-10.426271,"eighty":-5.376155,"marketCap":1367874660},{"date":"2025-12-12","current":-14.039791,"twenty":-13.99491,"median":-10.604143,"eighty":-5.393122,"marketCap":1371687551},{"date":"2025-12-19","current":-14.459326,"twenty":-14.050476,"median":-10.719003,"eighty":-5.431972,"marketCap":1412676130},{"date":"2025-12-26","current":-15.088628,"twenty":-14.119227,"median":-10.841851,"eighty":-5.476848,"marketCap":1474158998},{"date":"2026-01-02","current":-14.800808,"twenty":-14.281097,"median":-10.940782,"eighty":-5.513507,"marketCap":1446038926},{"date":"2026-01-09","current":-13.81051,"twenty":-14.281097,"median":-10.976093,"eighty":-5.513507,"marketCap":1349286816},{"date":"2026-01-16","current":-13.103154,"twenty":-14.237527,"median":-11.048158,"eighty":-5.513507,"marketCap":1280178166},{"date":"2026-01-23","current":-13.620256,"twenty":-14.172521,"median":-11.156822,"eighty":-5.535473,"marketCap":1330698972},{"date":"2026-01-30","current":-13.049493,"twenty":-14.13499,"median":-11.312246,"eighty":-5.592253,"marketCap":1274935441},{"date":"2026-02-06","current":-12.464095,"twenty":-14.128014,"median":-11.370643,"eighty":-5.617345,"marketCap":1217742075},{"date":"2026-02-13","current":-13.644647,"twenty":-14.087483,"median":-11.410917,"eighty":-5.641114,"marketCap":1333082029},{"date":"2026-02-20","current":-14.630067,"twenty":-14.14031,"median":-11.45735,"eighty":-5.660027,"marketCap":1429357528},{"date":"2026-02-27","current":-14.391029,"twenty":-14.240388,"median":-11.53826,"eighty":-5.735139,"marketCap":1406003571},{"date":"2026-03-06","current":-14.464204,"twenty":-14.259247,"median":-11.689515,"eighty":-5.790087,"marketCap":1413152741},{"date":"2026-03-13","current":-12.292686,"twenty":-14.284564,"median":-11.721364,"eighty":-5.811144,"marketCap":1370425569},{"date":"2026-03-20","current":-11.773881,"twenty":-14.259247,"median":-11.747556,"eighty":-5.859217,"marketCap":1312587588},{"date":"2026-03-27","current":-12.434179,"twenty":-14.240388,"median":-11.754185,"eighty":-5.89508,"marketCap":1386199565},{"date":"2026-04-02","current":-13.578981,"twenty":-14.21307,"median":-11.781033,"eighty":-5.908305,"marketCap":1513825524},{"date":"2026-04-10","current":-14.672331,"twenty":-14.286297,"median":-11.799793,"eighty":-5.924837,"marketCap":1635715486},{"date":"2026-04-17","current":-16.95336,"twenty":-14.342463,"median":-11.834618,"eighty":-5.953085,"marketCap":1890011406},{"date":"2026-04-24","current":-15.589888,"twenty":-14.384981,"median":-11.842483,"eighty":-5.987204,"marketCap":1738007454},{"date":"2026-05-01","current":-14.207247,"twenty":-14.395165,"median":-11.879676,"eighty":-6.003597,"marketCap":1583866549},{"date":"2026-05-08","current":-17.794666,"twenty":-14.442977,"median":-11.889648,"eighty":-6.018516,"marketCap":1908958386},{"date":"2026-05-15","current":-16.919116,"twenty":-14.478378,"median":-11.936812,"eighty":-6.027747,"marketCap":1815031955},{"date":"2026-05-22","current":-16.361832,"twenty":-14.513564,"median":-11.969573,"eighty":-6.033101,"marketCap":1755248294},{"date":"2026-05-29","current":-17.605688,"twenty":-14.602401,"median":-12.072587,"eighty":-6.039697,"marketCap":1888685426},{"date":"2026-06-05","current":-16.714035,"twenty":-14.636423,"median":-12.104204,"eighty":-6.052541,"marketCap":1793031568},{"date":"2026-06-12","current":-15.697551,"twenty":-14.689254,"median":-12.211886,"eighty":-6.082711,"marketCap":1683986170},{"date":"2026-06-18","current":-16.437623,"twenty":-14.725074,"median":-12.249449,"eighty":-6.104202,"marketCap":1763378872},{"date":"2026-06-26","current":-17.347109,"twenty":-14.756903,"median":-12.285702,"eighty":-6.170327,"marketCap":1860945807},{"date":"2026-07-02","current":-17.561106,"twenty":-14.865035,"median":-12.307654,"eighty":-6.173633,"marketCap":1883902733},{"date":"2026-07-10","current":-18.747004,"twenty":-14.94702,"median":-12.322165,"eighty":-6.184379,"marketCap":2011122364},{"date":"2026-07-17","current":-17.891017,"twenty":-15.011798,"median":-12.351888,"eighty":-6.210003,"marketCap":1919294660},{"date":"2026-07-24","current":-18.4483,"twenty":-15.085362,"median":-12.382727,"eighty":-6.318283,"marketCap":1979078322},{"date":"2026-07-31","current":-19.072457,"twenty":-15.112377,"median":-12.415031,"eighty":-6.358759,"marketCap":2046036022},{"date":"2026-08-07","current":-16.213135,"twenty":-15.201543,"median":-12.451899,"eighty":-6.368734,"marketCap":2223793556},{"date":"2026-08-14","current":-16.566431,"twenty":-15.503178,"median":-12.623979,"eighty":-6.396893,"marketCap":2272251624},{"date":"2026-08-21","current":-16.737832,"twenty":-15.582924,"median":-12.704769,"eighty":-6.419712,"marketCap":2295760985},{"date":"2026-08-28","current":-17.780229,"twenty":-15.689526,"median":-12.798103,"eighty":-6.426595,"marketCap":2438736277},{"date":"2026-09-01","current":-17.024666,"twenty":-15.697551,"median":-12.878752,"eighty":-6.429372,"marketCap":2335103179}],"updateTime":1788411422623},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2642747523","title":"Rapport Therapeutics shareholders elected Class II directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642747523","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642747523?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:12","pubTimestamp":1781122377,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics held its annual shareholder meeting on June 10, 2026.Shareholders backed the selection of three directors to serve until the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL4Zst73:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641512134","title":"Rapport Therapeutics (RAPP) Is Down 9% After Strong RAP-219 Data Outshines Rival Trial - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2641512134","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641512134?lang=en_us&edition=fundamental","pubTime":"2026-06-06 17:14","pubTimestamp":1780737265,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics recently reported extended efficacy data for its epilepsy candidate RAP-219, showing meaningful seizure reductions and reinforcing the drug’s therapeutic profile, while a rival’s trial disappointed. \nWith further RAP-219 results scheduled for presentation at the 2026 American Academy of Neurology Annual Meeting, the company’s position in epilepsy drug development has gained fresh attention.\nWe’ll now examine how RAP-219’s extended efficacy data shapes Rapport...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/rapport-therapeutics-rapp-is-down-9-after-strong-rap-219-dat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/news/rapport-therapeutics-rapp-is-down-9-after-strong-rap-219-dat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641696331","title":"RAPP Advances RAP-219 Into Phase 3, Raising the Stakes in Focal Epilepsy","url":"https://stock-news.laohu8.com/highlight/detail?id=2641696331","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641696331?lang=en_us&edition=fundamental","pubTime":"2026-06-05 00:33","pubTimestamp":1780590818,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ($RAPP) announced an update on their ongoing clinical study. The phase 3 study “A Phase 3, Randomized, Double-blind, Pla...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapp-advances-rap-219-into-phase-3-raising-the-stakes-in-focal-epilepsy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapp-advances-rap-219-into-phase-3-raising-the-stakes-in-focal-epilepsy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640917122","title":"BTIG Reaffirms Their Buy Rating on Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640917122","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640917122?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:19","pubTimestamp":1780399176,"startTime":"0","endTime":"0","summary":"BTIG analyst Kambiz Yazdi maintained a Buy rating on Rapport Therapeutics, Inc. yesterday and set a price target of $65.00. The company’s shares cl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-reaffirms-their-buy-rating-on-rapport-therapeutics-inc-rapp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639169586","title":"Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $743,673.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2639169586","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639169586?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:16","pubTimestamp":1779999405,"startTime":"0","endTime":"0","summary":"Third Rock Ventures V sold 18,572 shares of Rapport Therapeutics common stock on May 26, 2026.Sale priced at a weighted average of USD 40.05 per share.Third Rock Ventures VI reported 969,218 shares held indirectly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL1XTMhp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $743,673.08","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637332283","title":"Rapport Therapeutics, Inc. (RAPP) Receives a Buy from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2637332283","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637332283?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:56","pubTimestamp":1779364597,"startTime":"0","endTime":"0","summary":"BTIG analyst Kambiz Yazdi maintained a Buy rating on Rapport Therapeutics, Inc. today and set a price target of $65.00. According to TipRanks, Yazd...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-receives-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-receives-a-buy-from-btig-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380700","title":"Rapport Therapeutics Is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380700","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637380700?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:15","pubTimestamp":1779362100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 21, 2026 07:15 ET (11:15 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878689","title":"Rapport Therapeutics to present at Jefferies Global Healthcare Conference fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878689","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637878689?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:07","pubTimestamp":1779307628,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics will join the Jefferies Global Healthcare Conference in New York City for a fireside chat on June 3, 2026 at 8:45 a.m. ET.Management is also scheduled for a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8, 2026 at 1:20 p.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL9NgykC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1868837136.USD","LU2237443978.SGD","IE00B19Z3581.USD","BK4588","LU1894683264.USD","LU2095319765.USD","IE00BFXG1179.USD","IE00B64PRP62.GBP","LU0251142724.SGD","LU0868494617.USD","LU2237443895.HKD","IE00BSNM7G36.USD","LU0096364046.USD","LU2471134879.HKD","BK4585","IE00BN0W2W23.USD","IE0002270589.USD","IE00BGHQF748.EUR","RAPP","LU2471134523.USD","BK4552","GSX","IE0034235188.USD","LU0251131958.USD","LU1668664300.SGD","LU2237438978.USD","IE00BKPKM429.USD","NDAQ","LU0314104364.USD","IE0004086264.USD","LU0048573561.USD","BK4516","BK4533","LU0868494708.USD","LU0061475181.USD","IE00B19Z3B42.SGD","LU2471134796.USD","SG9999014013.SGD","LU1868836757.USD","LU0345770308.USD","LU0742534661.SGD","BK4112","LU0942090050.USD","BK4127","IE00BN0W2T93.GBP","LU2210150020.SGD","LU1868837300.USD","LU1804176565.USD","LU1868836914.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878904","title":"Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878904","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637878904?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:05","pubTimestamp":1779307500,"startTime":"0","endTime":"0","summary":"BOSTON and SAN DIEGO, May  20, 2026  (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and d","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298858/0/en/Rapport-Therapeutics-to-Participate-in-the-Jefferies-Global-Healthcare-Conference-and-Goldman-Sachs-47th-Annual-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","LU0251142724.SGD","LU2471134523.USD","LU0942090050.USD","XBI","BK4550","IE00B19Z3581.USD","LU0096364046.USD","LU2237438978.USD","IE00BSNM7G36.USD","BK4533","BK4137","LU2471134796.USD","BK4552","LABU","LU1868836591.USD","LU1868836914.USD","LU2237443382.USD","GSX","LU0345770993.USD","LU1804176565.USD","IE00BFXG1179.USD","LU1868836757.USD","LU2237443895.HKD","LU1894683264.USD","LU0345770308.USD","LU2237443978.SGD","BK4007","IE0004086264.USD","BK4588","LU1791807156.HKD","BK4585","HCSG","IE0002270589.USD","LU1868837300.USD","RAPP","LU0251131958.USD","IE00B19Z3B42.SGD","LU0868494708.USD","LU1668664300.SGD","LU2265009873.SGD","XLV","BK4127","LU2471134952.CNY","BK4504","LU2237443465.HKD","LU1894683348.USD","LU0128526141.USD","LU0048573561.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636866402","title":"Rapport Therapeutics Coverage Assumed by Truist Securities at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636866402","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636866402?lang=en_us&edition=fundamental","pubTime":"2026-05-20 02:42","pubTimestamp":1779216120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 19, 2026 14:42 ET (18:42 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636138002","title":"Rapport Therapeutics assumed with a Buy at Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2636138002","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636138002?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:00","pubTimestamp":1779145236,"startTime":"0","endTime":"0","summary":"Truist assumed coverage of Rapport Therapeutics (RAPP) with a Buy rating with a price target of $56, up from $44. The firm’s thesis is largely cons...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-assumed-with-a-buy-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-assumed-with-a-buy-at-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635480754","title":"Third Rock Ventures V disposes 133,618 Rapport Therapeutics shares for $5.38 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635480754","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635480754?lang=en_us&edition=fundamental","pubTime":"2026-05-14 07:07","pubTimestamp":1778713631,"startTime":"0","endTime":"0","summary":"Third Rock Ventures V sold 133,618 shares of Rapport Therapeutics common stock on May 11, 2026.Sale priced at weighted average USD 40.24 per share.Third Rock Ventures V held 6,299,097 shares following transaction.Separate Third Rock Ventures VI stake reported at 969,218 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 13, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2qDBmD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Third Rock Ventures V disposes 133,618 Rapport Therapeutics shares for $5.38 million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634925871","title":"Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $11,096,094.77","url":"https://stock-news.laohu8.com/highlight/detail?id=2634925871","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634925871?lang=en_us&edition=fundamental","pubTime":"2026-05-12 05:07","pubTimestamp":1778533675,"startTime":"0","endTime":"0","summary":"Third Rock Ventures V, L.P., a 10% owner of Rapport Therapeutics , sold 276,513 common shares on May 7-8.Sales priced at USD 40.12 per share on May 7, USD 40.31 per share on May 8.Direct holdings fell to 6,432,715 shares following transactions.Separate indirect stake of 969,218 shares reported as held by Third Rock Ventures VI, L.P.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL5GLbNd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Third Rock Ventures V disposes of Rapport Therapeutics common shares worth $11,096,094.77","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633372834","title":"Rapport Therapeutics Price Target Maintained With a $53.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2633372834","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633372834?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:45","pubTimestamp":1778237100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RAPP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 06:45 ET (10:45 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633317267","title":"Rapport Therapeutics, Inc. (RAPP) Gets a Buy from JonesTrading","url":"https://stock-news.laohu8.com/highlight/detail?id=2633317267","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633317267?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:36","pubTimestamp":1778186189,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh reiterated a Buy rating on Rapport Therapeutics, Inc. today and set a price target of $50.00. According to TipRan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-gets-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-gets-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633120718","title":"Analyst Reiterates Buy on RAP-219 Developer as Accelerating Clinical Milestones and Multi-Indication Potential Enhance Risk‑Reward Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2633120718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633120718?lang=en_us&edition=fundamental","pubTime":"2026-05-08 02:06","pubTimestamp":1778177171,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Joseph Thome has maintained their bullish stance on RAPP stock, giving a Buy rating on April 22. Joseph Thome has given his Buy ra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-rap-219-developer-as-accelerating-clinical-milestones-and-multi-indication-potential-enhance-risk‑reward-profile-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-rap-219-developer-as-accelerating-clinical-milestones-and-multi-indication-potential-enhance-risk‑reward-profile-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633305122","title":"Rapport Therapeutics Advances RAP-219 Into Phase 3, Setting Up New Catalyst in Focal Seizure Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2633305122","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633305122?lang=en_us&edition=fundamental","pubTime":"2026-05-08 00:31","pubTimestamp":1778171466,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ($RAPP) announced an update on their ongoing clinical study. Rapport Therapeutics Inc. (RAPP) has announced a new Phase ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-advances-rap-219-into-phase-3-setting-up-new-catalyst-in-focal-seizure-market?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-advances-rap-219-into-phase-3-setting-up-new-catalyst-in-focal-seizure-market?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633126577","title":"Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633126577","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633126577?lang=en_us&edition=fundamental","pubTime":"2026-05-07 22:35","pubTimestamp":1778164553,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $20,000, consensus $6M. “We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-reports-q1-eps-42c-consensus-71c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-reports-q1-eps-42c-consensus-71c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633495841","title":"Rapport Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633495841","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633495841?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:31","pubTimestamp":1778153486,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryRapport Therapeutics Inc RAPP.OQ reported a quarterly adjusted loss of 42 cents per share for the quarter e","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL8N41K190:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633459211","title":"Rapport Therapeutics Q1 FY26 net loss narrows to $19.9 million; revenue rises to $20 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633459211","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633459211?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:03","pubTimestamp":1778151822,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics posted a Q1 net loss of USD 19.9 million, narrowing from USD 24.1 million a year earlier, while loss per share improved to USD 0.42 from USD 0.68.Collaboration revenue was USD 20 million versus no revenue a year earlier, while R&D expense rose to USD 32.7 million from USD 19.6 million.G&A expense climbed to USD 11.5 million from USD 7.5 million; cash, cash equivalents and short-term investments ended at USD 476.8 million, down from USD 490.5 million at year-end.Phase 2a follow-up data for RAP-219 in focal onset seizures showed a 90% median reduction in clinical seizures over baseline in weeks 9-12; RAP-219 half-life estimate was raised to 22 days from 14 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL1t8R84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RAPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":3,"totalSize":97,"code":"91000000","status":"200"}]}}